Drugs Containing Excipient (Inactive Ingredient) SODIUM CHLORIDE

Branded drugs containing SODIUM CHLORIDE excipient, and estimated key patent expiration / generic entry dates

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Eli Lilly and Company	AMYVID	florbetapir f 18	0002-1200	SODIUM CHLORIDE	2027-04-30
Eli Lilly and Company	TAUVID	flortaucipir f-18	0002-1210	SODIUM CHLORIDE	2032-05-26
Eli Lilly and Company	TAUVID	flortaucipir f-18	0002-1220	SODIUM CHLORIDE	2032-05-26
Eli Lilly and Company	MOUNJARO	tirzepatide	0002-1506	SODIUM CHLORIDE	2028-12-19
Eli Lilly and Company	ZEPBOUND	tirzepatide	0002-2506	SODIUM CHLORIDE	2027-12-20

Generic drugs containing SODIUM CHLORIDE excipient

Company	Ingredient	NDC	Excipient
Eli Lilly and Company	florbetapir f 18	0002-1200	SODIUM CHLORIDE
Eli Lilly and Company	flortaucipir f-18	0002-1210	SODIUM CHLORIDE
Eli Lilly and Company	flortaucipir f-18	0002-1220	SODIUM CHLORIDE
Eli Lilly and Company	galcanezumab-gnlm	0002-1436	SODIUM CHLORIDE
Eli Lilly and Company	tirzepatide	0002-1506	SODIUM CHLORIDE

Sodium Chloride Pharmaceutical Excipient Market Dynamics and Financial Trajectory

Last updated: September 24, 2026

Sodium chloride is a mature, high-volume pharmaceutical excipient with limited patent protection, low chemical differentiation, and demand tied mainly to parenteral, ophthalmic, nasal, oral, and dialysis products. Financial performance depends less on intellectual property than on regulatory qualification, compendial compliance, sterile manufacturing, supply continuity, energy costs, freight, and customer switching costs.

The market has a defensive financial profile. Volume growth is likely to track injectable drug production, hospital utilization, ophthalmic product demand, biologics formulation, and contract manufacturing. Unit-price expansion is constrained by abundant global salt supply and competition among qualified producers. The strongest margins are available in sterile, low-endotoxin, tightly documented grades rather than commodity sodium chloride.

What is sodium chloride’s role as a pharmaceutical excipient?

Sodium chloride is used as an excipient and, in some products, as an active ingredient. Its principal pharmaceutical functions are:

Function	Typical application
Tonicity adjustment	Injectable, ophthalmic, nasal and inhalation products
Osmolality control	Biologics, vaccines, parenteral formulations
Diluent or vehicle component	Oral and liquid formulations
Electrolyte replacement	Intravenous sodium chloride products
Process aid	Cell culture, purification and manufacturing solutions
Preservation-supporting component	Selected multidose or buffered formulations

The commercial distinction matters. Sodium chloride used to adjust tonicity in an injectable is an excipient. A 0.9% sodium chloride intravenous solution is generally regulated as a finished drug with sodium chloride as the active ingredient. A manufacturer can therefore sell the same chemical substance into both the excipient and active pharmaceutical ingredient supply chains, but the regulatory documentation and quality controls differ.

Sodium chloride is listed in the FDA Inactive Ingredient Database for multiple routes and dosage forms, subject to route-specific precedent and maximum potency information.[1] The United States Pharmacopeia-National Formulary establishes compendial requirements for Sodium Chloride, including identity, assay, impurities and quality attributes.[2]

How large is the pharmaceutical sodium chloride excipient market?

Public market reports generally combine sodium chloride with broader pharmaceutical excipients, specialty chemicals, electrolytes, or intravenous solutions. They do not provide a consistent, audited market size for sodium chloride used specifically as a pharmaceutical excipient.

The addressable market is best analyzed through supply tiers:

1. Commodity and technical salt.
2. Food and pharmaceutical-grade refined salt.
3. Compendial pharmaceutical-grade sodium chloride.
4. Sterile, low-endotoxin sodium chloride supplied for direct incorporation or aseptic processing.
5. Finished sodium chloride solutions and custom formulation components.

The excipient market is materially smaller by value than the total salt market, but it has higher qualification barriers and better price realization. Finished sterile saline products generate far more revenue per kilogram than bulk excipient sodium chloride because value is added through water-for-injection systems, sterile filling, packaging, quality release, and distribution.

Revenue pools by product form

Product form	Commercial value driver	Margin profile
Dry crystalline sodium chloride	Purity, particle size, packaging, documentation	Low to moderate
Sterile powder or sterile raw material	Sterilization, endotoxin control, aseptic handling	Moderate to high
Concentrated sodium chloride solution	Concentration accuracy and validated packaging	Moderate
0.9% sodium chloride injection	Sterile filling, containers, regulatory release	Higher than bulk salt
Custom electrolyte solution	Formulation, fill-finish, customer qualification	High relative to chemical input

The value of sodium chloride itself is a small part of the finished product cost. In a sterile injectable, manufacturing labor, cleanroom operations, container systems, quality testing, depreciation, freight, and shortage management usually have a greater impact on gross margin than the salt input.

What drives demand for pharmaceutical sodium chloride?

Demand is linked to pharmaceutical production volumes rather than discretionary consumer demand.

Injectable drugs and biologics

Parenteral formulations use sodium chloride to control osmolality and improve physiological compatibility. Growth in biologics, vaccines, peptides and other injectable therapies supports demand for high-purity excipients and formulation-grade salts. The effect is volume-positive but modest in value because sodium chloride is usually present at low concentrations.

The expansion of contract development and manufacturing organizations also supports demand. Each approved formulation requires a qualified excipient source, and commercial manufacturers often maintain dual-source strategies for critical materials.

Ophthalmic and nasal products

Sodium chloride is widely used in ophthalmic and nasal formulations. These products require control of microbial quality, particulate matter, endotoxins and tonicity. Preservative-free ophthalmic products can create higher demand for tightly controlled raw materials and single-dose packaging, although sodium chloride remains a low-cost formulation component.

Dialysis and electrolyte products

Dialysis fluids, irrigation solutions and electrolyte replacement products create stable demand. These applications are sensitive to concentration accuracy, impurity profiles and supply continuity. Product manufacturers may use long-term supplier qualification because a material failure can interrupt production of high-volume hospital products.

Oral and liquid dosage forms

Sodium chloride is used in selected oral solutions, rehydration products and liquid formulations. This segment is less technically demanding than sterile injectable use and has lower qualification barriers.

What is the financial trajectory for sodium chloride excipients?

The financial trajectory is likely to be stable in volume, modest in revenue growth and pressured in commodity pricing.

Financial variable	Expected direction	Main driver
Pharmaceutical-grade volume	Gradual growth	Injectable, ophthalmic and biologics production
Average selling price	Low single-digit movement over time	Inflation, qualification premium and supply conditions
Commodity-grade margin	Compressed	Global salt supply and buyer substitution
Sterile-grade margin	More resilient	Validation, endotoxin control and limited qualified capacity
Working capital	Moderate	Safety stock and customer-specific inventory
Capital expenditure	Targeted	Purification, sterile processing and quality systems
Pricing power	Limited in dry salt	Standardized chemistry and alternative suppliers
Pricing power in sterile supply	Higher	Qualification burden and shortage risk

Energy and logistics are important cost variables. Sodium chloride production is energy-intensive when it relies on evaporation, purification or thermal processing. Ocean freight, packaging resin, labor and utilities can materially affect delivered cost, especially for smaller regional buyers.

Bulk salt producers can operate with scale economics, but pharmaceutical customers do not purchase solely on price. They assess audit history, certificate-of-analysis consistency, change-control discipline, traceability, elemental impurities, microbial limits, endotoxin control and business continuity. These factors create a quality premium, although they do not create the pricing power associated with patented pharmaceutical ingredients.

Which companies compete in pharmaceutical-grade sodium chloride?

Competition is fragmented across salt producers, specialty excipient distributors, sterile injectable manufacturers and contract manufacturers.

Representative supplier categories include:

• Large industrial and specialty salt producers such as K+S, Cargill and Compass Minerals.
• Pharmaceutical raw-material distributors and processors such as Merck, Avantor and Spectrum Chemical.
• Sterile solution manufacturers such as Baxter, Fresenius Kabi, ICU Medical and B. Braun.
• Regional producers supplying compendial sodium chloride to local drug manufacturers.
• Contract manufacturers that purchase sodium chloride and incorporate it into finished sterile products.

The competitive landscape differs by product form. A dry compendial material may have several qualified suppliers. A sterile, validated material or a finished saline solution may have fewer approved sources because the buyer must qualify the complete manufacturing process, packaging configuration and site.

Supplier concentration is therefore higher at the finished-product level than at the chemical-input level. A hospital may face saline shortages even when sodium chloride itself is abundant because the constraint is often sterile filling capacity, container availability, quality release or distribution.

What FDA regulatory status applies to sodium chloride?

Sodium chloride has a dual regulatory position.

As an inactive ingredient

The FDA Inactive Ingredient Database provides precedent for sodium chloride in multiple dosage forms and routes.[1] Sponsors using sodium chloride as an excipient must still demonstrate that the proposed amount and formulation are safe, suitable and consistent with applicable FDA requirements.

The database does not eliminate the need for supplier qualification. A drug manufacturer remains responsible for the identity, strength, quality, purity and composition of the excipient under current good manufacturing practice requirements.[3]

As an active ingredient

Sodium chloride injection products are regulated as drug products. FDA-approved sodium chloride injections include products used for fluid and electrolyte replenishment, dilution and other clinical purposes. The finished product must meet requirements for sterility, particulate matter, container closure integrity, concentration and labeling.

This distinction affects commercial exposure. Excipient sales are usually governed by quality agreements and purchase orders. Finished saline products require drug applications, validated sterile manufacturing and compliance with the applicable drug product monograph and FDA manufacturing rules.

What is the Orange Book status of sodium chloride?

Sodium chloride as a general excipient does not have a standalone Orange Book patent estate. The Orange Book records patents and exclusivity associated with approved finished drug products, not generic chemical ownership of an old compendial excipient.[4]

For sodium chloride injection products, Orange Book analysis must be conducted at the product level. A manufacturer may list patents covering:

• Container systems.
• Specific formulations.
• Concentration ranges combined with other ingredients.
• Delivery devices.
• Stability-enhancing technologies.
• Manufacturing or packaging methods, where listing requirements are met.

Those patents generally protect the finished drug product or delivery system, not sodium chloride as a chemical substance.

What patents protect pharmaceutical sodium chloride?

No commercially significant composition-of-matter patent protects sodium chloride as a pharmaceutical excipient. Sodium chloride is an ancient, well-characterized inorganic compound, and its basic chemical identity is in the public domain.

Potential patent protection can exist around a finished product or manufacturing process:

Patent category	Relevance to sodium chloride
Composition of matter	No meaningful exclusivity for sodium chloride itself
Formulation patent	Possible when sodium chloride is combined with other active or inactive ingredients
Container patent	Possible for bags, vials, syringes or dual-chamber systems
Device patent	Possible for administration or delivery systems
Manufacturing patent	Possible for purification, sterilization or fill-finish processes
Method-of-use patent	Usually relates to the finished product’s clinical use, not the excipient
Trade secret	Relevant to process controls, supplier qualification and sterile operations

The practical moat is operational rather than legal. A supplier with validated processes, stable quality history and approved status at multiple customers can retain business even when competitors can chemically reproduce the material.

Are there Paragraph IV challenges for sodium chloride?

There is no conventional Paragraph IV challenge to sodium chloride as an excipient. Paragraph IV certifications apply to abbreviated new drug applications that reference approved drug products with listed patents under the Hatch-Waxman framework.[5]

A generic manufacturer seeking approval for a sodium chloride injection may submit a Paragraph IV certification against patents listed for the reference product. The dispute would concern the finished injection, container, formulation, delivery system or method of use. It would not challenge ownership of sodium chloride itself.

This distinction limits patent litigation risk for excipient producers. Their commercial exposure is more likely to arise from customer product litigation, supply contracts, recalls, quality investigations or manufacturing interruptions.

What formulation patents and manufacturing barriers exist?

The most defensible IP positions relate to systems in which sodium chloride is one component of a broader product.

Formulation barriers

Potential formulation barriers include:

• Narrow osmolality specifications for sensitive biologics.
• Compatibility with proteins, peptides or cell-based products.
• Low particulate and low endotoxin requirements.
• Stability across temperature and storage conditions.
• Preservative-free multidose delivery.
• Compatibility with plastic bags, elastomers and glass.
• Controlled concentration in concentrated electrolyte products.

These attributes may support patents in limited cases, but most commercial protection comes from know-how, validation and regulatory approval.

Manufacturing barriers

Manufacturing barriers are stronger than patent barriers. They include:

• Access to qualified high-purity salt sources.
• Purification and recrystallization capacity.
• Validated sterilization methods.
• Endotoxin and bioburden control.
• Water-for-injection systems.
• Aseptic filling and container closure validation.
• Compendial testing capability.
• Change-control and traceability systems.
• Regulatory inspection readiness.
• Approved status at multiple pharmaceutical customers.

A new supplier can produce sodium chloride chemically, but it cannot immediately reproduce a competitor’s qualification history at a regulated customer.

When does sodium chloride lose exclusivity?

Sodium chloride has no meaningful molecule-level exclusivity period to lose. It is already a public-domain substance.

Finished sodium chloride products may have regulatory exclusivity or patent terms linked to the specific product. Those rights depend on the reference product, application date, listed patents and any litigation or settlement. Generic entry can occur after applicable patents and exclusivities expire or after successful litigation or licensing.

The commercial risk is therefore product-specific:

Asset	Exclusivity risk
Bulk sodium chloride excipient	Minimal
Compendial dry salt	Minimal, subject to supplier qualification
Sterile sodium chloride raw material	Moderate operational barriers
Sodium chloride injection	Product-level patent and approval risk
Proprietary container or delivery system	Potentially significant
Custom electrolyte formulation	Moderate, depending on formulation IP

What licensing deals and settlement agreements affect sodium chloride?

There is no major licensing market for sodium chloride itself. Licensing activity generally concerns finished products, sterile manufacturing capacity, private-label supply, container technology or regional distribution rights.

Settlement agreements may arise in litigation involving branded or generic saline products, but those agreements would normally address the specific finished product and patents. They would not create exclusivity over sodium chloride as an excipient.

Commercial agreements are more likely to include:

• Multi-year supply contracts.
• Dual-source commitments.
• Minimum purchase volumes.
• Customer-specific specifications.
• Audit rights.
• Change-notification obligations.
• Recall and indemnification provisions.
• Price-adjustment formulas tied to energy or freight.

What generic entry risks exist for sodium chloride products?

Generic entry risk is high for simple sodium chloride injections because the active ingredient is old, the formulation is familiar and several manufacturers can produce comparable products. The main barriers are sterile manufacturing, shortage-prone packaging formats, FDA compliance and commercial distribution.

Risk is lower where a product has:

• A proprietary delivery system.
• A complex container closure.
• Multiple active ingredients.
• A narrow stability profile.
• A specialized concentration or presentation.
• Hospital-contract advantages.
• Limited qualified manufacturing capacity.

For excipient suppliers, generic entry is usually positive for volume but negative for price. More approved injectable manufacturers can expand total sodium chloride consumption while increasing procurement pressure on raw-material suppliers.

How strong is the sodium chloride patent estate?

The sodium chloride excipient patent estate is weak. Its defensibility rests on:

1. Regulatory qualification.
2. Manufacturing consistency.
3. Sterile capacity.
4. Supply reliability.
5. Customer integration.
6. Documentation and audit performance.

The absence of composition patents increases substitution risk. A pharmaceutical manufacturer can often qualify another source if the alternative meets the same compendial and customer-specific specifications. Switching remains costly because the customer may need comparative testing, stability work, regulatory documentation and process validation.

What is the investment outlook for pharmaceutical sodium chloride?

Sodium chloride is a defensive, low-volatility pharmaceutical material rather than a high-growth specialty excipient. Attractive investment exposure is more likely in:

• Sterile injectable manufacturing.
• High-purity excipient processing.
• Contract fill-finish.
• Regional supply capacity.
• Specialty packaging.
• Quality-controlled distribution.
• Shortage-prone hospital products.

Pure bulk salt production offers scale but limited pharmaceutical pricing power. The strongest financial trajectory is available to suppliers that move downstream from commodity salt into compendial, sterile and customer-qualified products.

Revenue exposure to sodium chloride alone is rarely disclosed by diversified suppliers. Investors should evaluate segment mix, capacity utilization, energy intensity, customer concentration, regulatory inspection history, sterile fill-finish capacity and exposure to hospital saline pricing rather than relying on total company revenue.

Key Takeaways

• Sodium chloride is a mature pharmaceutical excipient with stable demand and limited patent risk.
• The highest-value opportunities are in sterile, low-endotoxin and customer-qualified grades.
• Bulk sodium chloride has weak pricing power because the chemical is standardized and widely available.
• Finished saline products generate substantially more value than the salt input but carry higher regulatory and manufacturing risk.
• Sodium chloride has no meaningful standalone composition-of-matter patent estate.
• Paragraph IV litigation can affect finished sodium chloride injections but does not apply to the excipient itself.
• Manufacturing validation, sterility, quality systems and supply reliability are stronger barriers than IP.
• Generic entry is likely to increase volume while pressuring prices for simple injectable products.
• Financial performance should be assessed through downstream exposure, sterile capacity and supply contracts rather than commodity salt volumes alone.

FAQs

Is sodium chloride an excipient or an active pharmaceutical ingredient?

It can be either. It is an excipient when used to adjust tonicity or support formulation performance. It is an active ingredient in products such as sodium chloride injection used for fluid and electrolyte replacement.

Does sodium chloride require an FDA Drug Master File?

A Drug Master File may be used for manufacturing and quality information, but FDA does not require every excipient supplier to maintain one. Customers may require a DMF, full technical package or supplier-specific qualification file as part of procurement.

Can pharmaceutical manufacturers substitute one sodium chloride supplier for another?

Yes, but substitution usually requires quality assessment, comparative testing, change control and, depending on the product, regulatory evaluation. Sterile and injectable applications have the highest switching burden.

Is pharmaceutical-grade sodium chloride subject to shortages?

The chemical itself is generally less shortage-prone than finished saline products. Shortages can result from sterile filling constraints, packaging shortages, plant interruptions, quality failures, freight disruption or concentrated supplier capacity.

Does sodium chloride have biosimilar exposure?

No. Sodium chloride is a small inorganic compound and is not a biologic. Biosimilar pathways do not apply. Competitive risk arises from generic drugs and alternative qualified excipient suppliers.

References

1. U.S. Food and Drug Administration. (n.d.). Inactive Ingredient Database. https://www.accessdata.fda.gov/scripts/cder/iig/index.cfm
2. United States Pharmacopeial Convention. (2024). Sodium Chloride monograph. In United States Pharmacopeia and National Formulary.
3. U.S. Food and Drug Administration. (2024). Current good manufacturing practice requirements for finished pharmaceuticals, 21 C.F.R. Parts 210 and 211.
4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files
5. U.S. Food and Drug Administration. (2024). Abbreviated new drug application submissions: Patent certifications and the Paragraph IV patent certification process. https://www.fda.gov/drugs/abbreviated-new-drug-application-anda/anda-submissions-patent-certifications-and-statement-nda-applicants-suitability-petitions-relevant-patents-or-exclusivity